Bevacizumab and Combination Chemotherapy in Treating Patients With Peripheral T-Cell Lymphoma or Natural Killer Cell Neoplasms

INCLUSION CRITERIA:

* Diagnosis of peripheral T-cell or natural killer cell neoplasm

  * Any stage disease allowed
  * HTLV-positive tumors allowed
* At least one objective measurable disease parameter. Abnormal positron emission tomography scans are not considered evidence of measurable disease unless results are confirmed by CT scan or other appropriate imaging techniques
* Age 18 and over
* ECOG Performance status 0-2
* Absolute neutrophil count ≥ 1,000/mm\^3(500/mm\^3 if due to bone marrow involvement with lymphoma)
* Platelet count ≥ 100,000/mm\^3(50,000/mm\^3 if due to bone marrow involvement with lymphoma)
* Bilirubin ≤ 2.0 mg/dL (≤ 3 times upper limit of normal \[ULN\] if due to hepatic involvement with lymphoma)
* AST ≤ 2 times ULN (5 times ULN if due to hepatic involvement with lymphoma)
* PT, INR, and PTT ≤ 1.5 times normal
* Creatinine ≤ 2.0 mg/dL
* Urinary protein:creatinine ratio ≤ 1
* History of deep venous thrombosis allowed provided patient is on a stable dose of anticoagulants for at least 2 weeks prior to study entry
* LVEF ≥ 50%
* History of pulmonary embolism allowed provided patient is on a stable dose of anticoagulants for at least 2 weeks prior to study entry
* One prior cycle of CHOP for PTCL allowed
* More than 4 weeks since prior major invasive surgery or open biopsy
* At least 7 days since prior minor surgery. Peripheral lymph node core biopsy, bone marrow biopsy, fine needle aspiration, skin biopsy, or central line placement are not considered minor surgical procedures
* More than 7 days since prior and no concurrent anti-platelet drugs (e.g., ticlopidine, clopidogrel, or cilostazol) except aspirin or other nonsteroidal anti-inflammatory drugs
* Concurrent anticoagulants allowed provided patient is on a stable dose

  * INR must be stable for at least 2 weeks prior to study entry
  * PT/INR and/or PTT must be closely monitored and levels kept within acceptable range for underlying thrombotic disease
  * Concurrent heparin flush for maintenance of central line patency allowed

EXCLUSION CRITERIA:

* Anaplastic lymphoma kinase (ALK)-positive T-cell large cell lymphoma. ALK-negative T-cell large cell lymphoma allowed
* Cutaneous T-cell lymphoma
* History of or current radiographic evidence of CNS metastasis, including previously treated, resected, or asymptomatic brain lesions or leptomeningeal involvement
* Evidence of bleeding diathesis or coagulopathy
* Cerebrovascular accident within the past 6 months
* Myocardial infarction within the past 6 months
* Unstable angina within the past 6 months
* New York Heart Association class II-IV congestive heart failure
* Uncontrolled hypertension (i.e., systolic blood pressure \[BP\] \> 150 mm Hg or diastolic BP \> 100 mm Hg)
* Other clinically significant cardiovascular or peripheral vascular disease
* Abdominal fistula within the past 6 months
* Gastrointestinal perforation within the past 6 months
* Intra-abdominal abscess within the past 6 months
* Concurrent major surgery
* Pregnant or nursing. Female patients must have negative pregnancy test. Fertile patients must use effective contraception
* History of active seizures
* Significant traumatic injury within the past 4 weeks
* Non-healing ulcer (unless involved with lymphoma)
* Bone fracture
* Active infection requiring parenteral antibiotics
* HIV positivity
* Other active malignancy within the past 6 months except carcinoma in situ of the cervix or basal cell carcinoma of the skin